Journal of Cardiovascular Pharmacology最新文献_第10页

Sulforaphane Improves Redox Homeostasis and Right Ventricular Contractility in a Model of Pulmonary Hypertension. 红豆杉能改善肺动脉高压模型中的氧化还原稳态和右心室收缩力

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2024-06-01 DOI: 10.1097/FJC.0000000000001557

Adriana Conzatti, Rafael Colombo, Rafaela Siqueira, Cristina Campos-Carraro, Patrick Turck, Alexandre Luz de Castro, Adriane Belló-Klein, Alex Sander da Rosa Araujo

{"title":"Sulforaphane Improves Redox Homeostasis and Right Ventricular Contractility in a Model of Pulmonary Hypertension.","authors":"Adriana Conzatti, Rafael Colombo, Rafaela Siqueira, Cristina Campos-Carraro, Patrick Turck, Alexandre Luz de Castro, Adriane Belló-Klein, Alex Sander da Rosa Araujo","doi":"10.1097/FJC.0000000000001557","DOIUrl":"10.1097/FJC.0000000000001557","url":null,"abstract":"Abstract: Pulmonary arterial hypertension (PAH) is characterized by increased pulmonary vascular resistance (PVR), imposing overload on the right ventricle (RV) and imbalance of the redox state. Our study investigated the influence of treatment with sulforaphane (SFN), found in cruciferous vegetables, on RV remodeling and redox homeostasis in monocrotaline (MCT)-induced PAH. Male Wistar rats were separated into 4 groups: control (CTR); CTR + SFN; MCT; and MCT + SFN. PAH induction was implemented by a single dose of MCT (60 mg/kg intraperitoneally). Treatment with SFN (2.5 mg/kg/day intraperitoneally) started on the seventh day after the MCT injection and persisted for 2 weeks. After 21 days of PAH induction, echocardiographic, hemodynamic, and oxidative stress evaluation was performed. The MCT group showed an increase in RV hypertrophy, RV systolic area, RV systolic, mean pulmonary artery pressure, and PVR and exhibited a decrease in the RV outflow tract acceleration time/ejection time ratio, RV fractional shortening, and tricuspid annular plane systolic excursion compared to CTR ( P < 0.05). SFN-treated PAH attenuated detrimental changes in tricuspid annular plane systolic excursion, mean pulmonary artery pressure, and PVR parameters. Catalase levels and the glutathione/Glutathione disulfide (GSSG) ratio were diminished in the MCT group compared to CTR ( P < 0.05). SFN increased catalase levels and normalized the glutathione/GSSG ratio to control levels ( P < 0.05). Data express the benefit of SFN treatment on the cardiac function of rats with PAH associated with the cellular redox state.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"612-620"},"PeriodicalIF":2.6,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140318394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting Pharmacotherapies for Inflammatory and Cardiorenal Endpoints in Kidney Disease. 针对肾脏疾病炎症和心肾终点的药物治疗。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2024-06-01 DOI: 10.1097/FJC.0000000000001482

Daniel M Huck, Leo F Buckley, Anil Chandraker, Ron Blankstein, Brittany Weber

{"title":"Targeting Pharmacotherapies for Inflammatory and Cardiorenal Endpoints in Kidney Disease.","authors":"Daniel M Huck, Leo F Buckley, Anil Chandraker, Ron Blankstein, Brittany Weber","doi":"10.1097/FJC.0000000000001482","DOIUrl":"10.1097/FJC.0000000000001482","url":null,"abstract":"Abstract: Inflammation is an important contributor to excess cardiovascular risk and progressive renal injury in people with chronic kidney disease (CKD). Dysregulation of the innate and adaptive immune system is accelerated by CKD and results in increased systemic inflammation, a heightened local vascular inflammatory response leading to accelerated atherosclerosis, and dysfunction of the cardiac and renal endothelium and microcirculation. Understanding and addressing the dysregulated immune system is a promising approach to modifying cardiorenal outcomes in people with CKD. However, targeted pharmacotherapies adopted from trials of non-CKD and cardiorheumatology populations are only beginning to be developed and tested in human clinical trials. Pharmacotherapies that inhibit the activation of the NOD-like receptor protein 3 inflammasome and the downstream cytokines interleukin-1 and interleukin-6 are the most well-studied. However, most of the available evidence for efficacy is from small clinical trials with inflammatory and cardiorenal biomarker endpoints, rather than cardiovascular event endpoints, or from small CKD subgroups in larger clinical trials. Other pharmacotherapies that have proven beneficial for cardiorenal endpoints in people with CKD have been found to have pleiotropic anti-inflammatory benefits including statins, mineralocorticoid receptor antagonists, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 agonists. Finally, emerging therapies in CKD such as interleukin-6 inhibition, small-interfering RNA against lipoproteins, aryl hydrocarbon receptor inhibitors, and therapies adopted from the renal transplant population including mammalian target of rapamycin inhibitors and T regulatory cell promoters may have benefits for cardiorenal and inflammatory endpoints but require further investigation in clinical trials.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"511-521"},"PeriodicalIF":2.6,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10912396/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10182840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

N-Acetylcysteine: The Next Best Thing for Cardiovascular Interventions and Surgery? N-乙酰半胱氨酸：心血管介入和手术的下一个最佳选择？

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2024-06-01 DOI: 10.1097/FJC.0000000000001558

Beatrice Simeone, Erica Rocco, Giuseppe Biondi-Zoccai, Francesco Versaci

引用次数: 0

Chronotropic Responses to GLP-1 Receptor Agonists and Sitagliptin in Atria From Diabetic Rats. 糖尿病大鼠心房对 GLP-1 受体激动剂和西他列汀的顺时针反应

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2024-06-01 DOI: 10.1097/FJC.0000000000001564

Esra Akcabag, Zinnet Sevval Aksoyalp, Feride Oner, Zeliha Bayram, Gul Ozbey, Cahit Nacitarhan, Sebahat Ozdem, Arda Tasatargil, Sadi S Ozdem

{"title":"Chronotropic Responses to GLP-1 Receptor Agonists and Sitagliptin in Atria From Diabetic Rats.","authors":"Esra Akcabag, Zinnet Sevval Aksoyalp, Feride Oner, Zeliha Bayram, Gul Ozbey, Cahit Nacitarhan, Sebahat Ozdem, Arda Tasatargil, Sadi S Ozdem","doi":"10.1097/FJC.0000000000001564","DOIUrl":"10.1097/FJC.0000000000001564","url":null,"abstract":"Abstract: Type 2 diabetes mellitus increases the risk of cardiovascular diseases. Therefore, elucidation of the cardiovascular effects of antidiabetics is crucial. Incretin-based therapies are increasingly used for type 2 diabetes mellitus treatment as monotherapy and in combination. We aimed to study the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sitagliptin on beating rates in isolated atria from diabetic rats. The chronotropic responses to GLP-1 RAs and sitagliptin as monotherapy and in combinations with metformin, pioglitazone, and glimepiride in isolated atria from control and diabetic rats were determined. GLP-1 (7-36), GLP-1 (9-36), and exendin-4 (1-39) produced increases in beating rates in both control and diabetic rat atria. However, sitagliptin increased the beating frequency only in the diabetic group. Exendin (9-39), nitro- l -arginine methyl ester hydrochloride, and indomethacin blocked responses to GLP-1 RAs but not the response to sitagliptin. Glibenclamide, 4-aminopyridine, apamin, charybdotoxin, superoxide dismutase, and catalase incubations did not change responses to GLP-1 RAs and sitagliptin. GLP-1 RAs increase beating rates in isolated rat atrium through GLP-1 receptor, nitric oxide, and cyclooxygenase pathways but not potassium channels and reactive oxygen radicals.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"621-634"},"PeriodicalIF":2.6,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140318390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of Interleukin-17 Inhibitors With Hypertension in Patients With Autoimmune Diseases: A Systematic Review and Meta-analysis on Randomized Controlled Trials. IL-17 抑制剂与自身免疫性疾病患者高血压的关系：随机对照试验的系统综述和元分析》。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2024-06-01 DOI: 10.1097/FJC.0000000000001547

Kexin Jiang, Yuheng Jia, Li Chen, Fangyang Huang, Mao Chen

引用次数: 0

Atherosclerotic Plaque Erosion: Mechanisms, Clinical Implications, and Potential Therapeutic Strategies-A Review. 动脉粥样硬化斑块侵蚀：机制、临床意义和潜在治疗策略--综述。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2024-06-01 DOI: 10.1097/FJC.0000000000001554

Sharon Bruoha, Mattia Galli, Pierre Sabouret, Chaim Yosefy, Louay Taha, Felice Gragnano, Michael P Savage, Mony Shuvy, Giuseppe Biondi-Zoccai, Michael Glikson, Elad Asher

引用次数: 0

N-Acetylcysteine to Reduce Mortality for Patients Requiring Cardiac Catheterization or Cardiac Surgery: A Systematic Review and Meta-analysis. N-乙酰半胱氨酸降低心导管检查或心脏手术患者的死亡率：系统综述与元分析》。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2024-06-01 DOI: 10.1097/FJC.0000000000001551

Clement Gakuba, Alexandru-Daniel Dumitrascu, Pierre-Emmanuel Marsan, Damien Legallois, Jean-Luc Hanouz, Denis Vivien, Sara Martinez de Lizarrondo, Maxime Gauberti, Damiano Cerasuolo

{"title":"N-Acetylcysteine to Reduce Mortality for Patients Requiring Cardiac Catheterization or Cardiac Surgery: A Systematic Review and Meta-analysis.","authors":"Clement Gakuba, Alexandru-Daniel Dumitrascu, Pierre-Emmanuel Marsan, Damien Legallois, Jean-Luc Hanouz, Denis Vivien, Sara Martinez de Lizarrondo, Maxime Gauberti, Damiano Cerasuolo","doi":"10.1097/FJC.0000000000001551","DOIUrl":"10.1097/FJC.0000000000001551","url":null,"abstract":"Abstract: Multimers of von Willebrand factor play a critical role in various processes inducing morbidity and mortality in cardiovascular-risk patients. With the ability to reduce von Willebrand factor multimers, N-acetylcysteine (NAC) could reduce mortality in patients undergoing coronary catheterization or cardiac surgery. However, its impact in perioperative period has never been studied so far in regard of its potential cardiovascular benefits. Then, 4 databases were searched for randomized controlled trials that compared in-hospital mortality between an experimental group, with NAC, and a control group without NAC, in patients undergoing coronary catheterization or cardiac surgery. The primary efficacy outcome was in-hospital mortality. Secondary outcomes were the occurrence of thrombotic events, major cardiovascular events, myocardial infarction, and contrast-induced nephropathy. The safety outcome was occurrence of hemorrhagic events. Nineteen studies totaling 3718 patients were included. Pooled analysis demonstrated a reduction of in-hospital mortality associated with NAC: odds ratio, 0.60; 95% confidence interval, 0.39-0.92; P = 0.02. The occurrence of secondary outcomes was not significantly reduced with NAC except for contrast-induced nephropathy. No difference was reported for hemorrhagic events. Subgroup analyses revealed a life-saving effect of NAC in a dose-dependent manner with reduction of in-hospital mortality for the NAC high-dose group, but not for the NAC standard-dose (<3500-mg) group. In conclusion, without being able to conclude on the nature of the mechanism involved, our review suggests a benefit of NAC in cardiovascular-risk patients in perioperative period in terms of mortality and supports prospective confirmatory studies.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"580-587"},"PeriodicalIF":2.6,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140101639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interleukin-1 Inhibition for the Prevention and Treatment of Heart Failure. 白细胞介素-1抑制在预防和治疗心力衰竭中的作用。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2024-06-01 DOI: 10.1097/FJC.0000000000001497

Ehsan Jafree, Marco Giuseppe Del Buono, Justin M Canada, Salvatore Carbone, Jordana Kron, Ross Arena, Benjamin Van Tassell, Antonio Abbate, Cory R Trankle

{"title":"Interleukin-1 Inhibition for the Prevention and Treatment of Heart Failure.","authors":"Ehsan Jafree, Marco Giuseppe Del Buono, Justin M Canada, Salvatore Carbone, Jordana Kron, Ross Arena, Benjamin Van Tassell, Antonio Abbate, Cory R Trankle","doi":"10.1097/FJC.0000000000001497","DOIUrl":"10.1097/FJC.0000000000001497","url":null,"abstract":"Abstract: Heart failure (HF) is a complex syndrome that remains a leading cause of morbidity and mortality worldwide. Abundant evidence suggests inflammation plays a key role in the development and perpetuation of HF, but there are currently no anti-inflammatory treatments approved for use in HF. Interleukin-1, the prototypical proinflammatory cytokine, has been implicated in adverse cardiac remodeling and left ventricular dysfunction. Multiple early phase clinical trials using interleukin-1 blockade in patients at risk for or diagnosed with HF have suggested favorable safety and efficacy in reducing inflammatory biomarkers, as well as positive signals in surrogate and clinical end points. Additional large scale clinical trials are urgently needed to confirm the safety and efficacy of this therapeutic approach specifically in HF. In this narrative review, we discuss current evidence regarding interleukin-1 blockade in the prevention and treatment of HF.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"522-530"},"PeriodicalIF":2.6,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11004086/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41182683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Practical Guide to Understanding and Treating Peripheral Artery Disease. 了解和治疗外周动脉疾病实用指南》。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2024-06-01 DOI: 10.1097/FJC.0000000000001556

Maya R Chilbert, Ashley E Woodruff, Kelly C Rogers

{"title":"A Practical Guide to Understanding and Treating Peripheral Artery Disease.","authors":"Maya R Chilbert, Ashley E Woodruff, Kelly C Rogers","doi":"10.1097/FJC.0000000000001556","DOIUrl":"10.1097/FJC.0000000000001556","url":null,"abstract":"Abstract: Peripheral arterial disease (PAD) is the third leading cause of atherosclerotic morbidity after coronary heart disease and stroke yet is widely underdiagnosed and undertreated. Treatment of risk factors such as diabetes and cigarette smoking can benefit patients with PAD. Patients should have adequate blood pressure and lipid control to decrease clinical manifestations and symptoms of PAD. Use of antithrombotic medications should be individualized to the patient depending on the presence of symptoms, revascularization, and comorbidities. All patient care providers, including physicians, pharmacists, nurse practitioners, and physician assistants, should incorporate PAD screening in their at-risk patients to improve access for appropriate earlier diagnosis, initiation of guideline directed therapy, and risk factor modification to reduce both major adverse CV and limb outcomes. The purpose of this narrative review is to provide an overview of PAD and summarize clinical trial evidence and guideline recommendations for screening and treatment to increase awareness among health care providers to ultimately have a positive impact on patient care.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"565-579"},"PeriodicalIF":2.6,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140059511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interleukin-1 Blockers for the Treatment of Recurrent Pericarditis: Pathophysiology, Patient-Reported Outcomes, and Perspectives. 治疗复发性心包炎的白介素-1 阻滞剂：病理生理学、患者报告结果和前景。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2024-06-01 DOI: 10.1097/FJC.0000000000001435

Georgia K Thomas, Aldo Bonaventura, Alessandra Vecchié, Benjamin van Tassell, Massimo Imazio, Allan Klein, Sushil Allen Luis, Antonio Abbate

引用次数: 0